NCT01496196View on ClinicalTrials.gov

The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis

PHASE3UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

February 29, 2016

Conditions
Hemoptisis
Interventions
DRUG

tranexamic acid

500 mg/5 ml 3-4 times a day

DRUG

tranexamic acid

500 mg/5 ml 3-4 times a day

Trial Locations (1)

972

RECRUITING

Pulmonary department, Meir Medical Center, Kfar Saba

Sponsors
All Listed Sponsors
lead

Meir Medical Center

OTHER

NCT01496196 - The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis | Biotech Hunter | Biotech Hunter